Gene Review:
PDE5A - phosphodiesterase 5A, cGMP-specific
Homo sapiens
Synonyms:
CGB-PDE, CN5A, PDE5, cGMP-binding cGMP-specific phosphodiesterase, cGMP-specific 3',5'-cyclic phosphodiesterase
Dousa,
Lin,
Giembycz,
Fisher,
Smith,
Pillar,
St Denis,
Cheng,
Loughney,
Hill,
Florio,
Uher,
Rosman,
Wolda,
Jones,
Howard,
McAllister-Lucas,
Sonnenburg,
Francis,
Corbin,
Beavo,
Ferguson,
Brindis,
Kloner,
Mayer,
Stief,
Truss,
Uckert,
Lin,
Lau,
Tu,
Lue,
Porst,
Wharton,
Strange,
Møller,
Growcott,
Ren,
Franklyn,
Phillips,
Wilkins,
Murthy,
- Modeling and mutational analysis of the GAF domain of the cGMP-binding, cGMP-specific phosphodiesterase, PDE5. Sopory, S., Balaji, S., Srinivasan, N., Visweswariah, S.S. FEBS Lett. (2003)
- Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Piazza, G.A., Thompson, W.J., Pamukcu, R., Alila, H.W., Whitehead, C.M., Liu, L., Fetter, J.R., Gresh, W.E., Klein-Szanto, A.J., Farnell, D.R., Eto, I., Grubbs, C.J. Cancer Res. (2001)
- Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Giembycz, M.A. Current opinion in pharmacology. (2005)
- Tissue expression, distribution, and regulation of PDE5. Lin, C.S. Int. J. Impot. Res. (2004)
- Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Wharton, J., Strange, J.W., Møller, G.M., Growcott, E.J., Ren, X., Franklyn, A.P., Phillips, S.C., Wilkins, M.R. Am. J. Respir. Crit. Care Med. (2005)
- Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis. Küthe, A., Mägert, H., Uckert, S., Forssmann, W.G., Stief, C.G., Jonas, U. Eur. Urol. (2000)
- Modulatory effect of sildenafil in diabetes and electroconvulsive shock-induced cognitive dysfunction in rats. Patil, C.S., Singh, V.P., Kulkarni, S.K. Pharmacological reports : PR. (2006)
- Sildenafil in patients with cardiovascular disease. Brindis, R.G., Kloner, R.A. Am. J. Cardiol. (2003)
- Transient global amnesia after intake of tadalafil, a PDE-5 inhibitor: a possible association? Schiefer, J., Sparing, R. Int. J. Impot. Res. (2005)
- Phosphodiesterase inhibitors in female sexual dysfunction. Mayer, M., Stief, C.G., Truss, M.C., Uckert, S. World journal of urology. (2005)
- Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. Serafini, P., Meckel, K., Kelso, M., Noonan, K., Califano, J., Koch, W., Dolcetti, L., Bronte, V., Borrello, I. J. Exp. Med. (2006)
- Signaling for contraction and relaxation in smooth muscle of the gut. Murthy, K.S. Annu. Rev. Physiol. (2006)
- PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. Rybalkin, S.D., Rybalkina, I.G., Shimizu-Albergine, M., Tang, X.B., Beavo, J.A. EMBO J. (2003)
- Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling. Mullershausen, F., Friebe, A., Feil, R., Thompson, W.J., Hofmann, F., Koesling, D. J. Cell Biol. (2003)
- Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. Uckert, S., Küthe, A., Stief, C.G., Jonas, U. World journal of urology. (2001)
- Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Dousa, T.P. Kidney Int. (1999)
- Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Morelli, A., Filippi, S., Mancina, R., Luconi, M., Vignozzi, L., Marini, M., Orlando, C., Vannelli, G.B., Aversa, A., Natali, A., Forti, G., Giorgi, M., Jannini, E.A., Ledda, F., Maggi, M. Endocrinology (2004)
- A cyclic nucleotide PDE5 inhibitor corrects defective mucin secretion in submandibular cells containing antibody directed against the cystic fibrosis transmembrane conductance regulator protein. McPherson, M.A., Pereira, M.M., Lloyd Mills, C., Murray, K.J., Dormer, R.L. FEBS Lett. (1999)
- Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens. Mancina, R., Filippi, S., Marini, M., Morelli, A., Vignozzi, L., Salonia, A., Montorsi, F., Mondaini, N., Vannelli, G.B., Donati, S., Lotti, F., Forti, G., Maggi, M. Mol. Hum. Reprod. (2005)
- Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. Fisher, D.A., Smith, J.F., Pillar, J.S., St Denis, S.H., Cheng, J.B. J. Biol. Chem. (1998)
- Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase. Loughney, K., Hill, T.R., Florio, V.A., Uher, L., Rosman, G.J., Wolda, S.L., Jones, B.A., Howard, M.L., McAllister-Lucas, L.M., Sonnenburg, W.K., Francis, S.H., Corbin, J.D., Beavo, J.A., Ferguson, K. Gene (1998)
- Identification of three alternative first exons and an intronic promoter of human PDE5A gene. Lin, C.S., Lau, A., Tu, R., Lue, T.F. Biochem. Biophys. Res. Commun. (2000)
- Genomic origin and transcriptional regulation of two variants of cGMP-binding cGMP-specific phosphodiesterases. Kotera, J., Fujishige, K., Imai, Y., Kawai, E., Michibata, H., Akatsuka, H., Yanaka, N., Omori, K. Eur. J. Biochem. (1999)
- L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Valente, E.G., Vernet, D., Ferrini, M.G., Qian, A., Rajfer, J., Gonzalez-Cadavid, N.F. Nitric Oxide (2003)
- Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Yanaka, N., Kotera, J., Ohtsuka, A., Akatsuka, H., Imai, Y., Michibata, H., Fujishige, K., Kawai, E., Takebayashi, S., Okumura, K., Omori, K. Eur. J. Biochem. (1998)
- Identification and regulation of human PDE5A gene promoter. Lin, C.S., Chow, S., Lau, A., Tu, R., Lue, T.F. Biochem. Biophys. Res. Commun. (2001)
- Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. Huai, Q., Wang, H., Zhang, W., Colman, R.W., Robinson, H., Ke, H. Proc. Natl. Acad. Sci. U.S.A. (2004)
- Structural basis for the activity of drugs that inhibit phosphodiesterases. Card, G.L., England, B.P., Suzuki, Y., Fong, D., Powell, B., Lee, B., Luu, C., Tabrizizad, M., Gillette, S., Ibrahim, P.N., Artis, D.R., Bollag, G., Milburn, M.V., Kim, S.H., Schlessinger, J., Zhang, K.Y. Structure (Camb.) (2004)
- Specific localized expression of cGMP PDEs in Purkinje neurons and macrophages. Bender, A.T., Beavo, J.A. Neurochem. Int. (2004)
- Human salivary gustin is a potent activator of calmodulin-dependent brain phosphodiesterase. Law, J.S., Nelson, N., Watanabe, K., Henkin, R.I. Proc. Natl. Acad. Sci. U.S.A. (1987)
- Genomic organization of the human phosphodiesterase PDE11A gene. Evolutionary relatedness with other PDEs containing GAF domains. Yuasa, K., Kanoh, Y., Okumura, K., Omori, K. Eur. J. Biochem. (2001)
- IC351 (tadalafil, Cialis): update on clinical experience. Porst, H. Int. J. Impot. Res. (2002)
- Inhibitory effects of furoquinoline alkaloids from Melicope confusa and Dictamnus albus against human phosphodiesterase 5 (hPDE5A) in vitro. Nam, K.W., Je, K.H., Shin, Y.J., Kang, S.S., Mar, W. Arch. Pharm. Res. (2005)